Novel Drug Delivery System Troubleshooting

Troubleshooting nanoparticulate and vesicular delivery systems requires application of the colloidal chemistry principles established in the chapter on...

Troubleshooting nanoparticulate and vesicular delivery systems requires application of the colloidal chemistry principles established in the chapter on novel drug delivery systems, since the failure modes characteristic of these systems differ substantially from those encountered in conventional solid dosage forms. Excessively large particle size, typically defined as exceeding 500 nanometres for systems intended for intravenous administration, most commonly results from inadequate sonication energy or duration during preparation, and is addressed by increasing sonication cycles, transitioning to a probe sonicator offering higher energy input than a bath sonicator, or reducing the polymer or lipid concentration to lower the viscosity of the dispersed phase during particle formation.

An elevated Polydispersity Index, generally regarded as problematic above approximately 0.3, reflects a broad or multimodal particle size distribution and is typically remediated through post-preparation filtration, commonly through a 0.45 micrometre membrane, prior to particle size analysis, optimisation of the stabiliser concentration, most frequently polyvinyl alcohol, or a complete re-processing of the batch under revised preparation parameters. Low encapsulation efficiency, generally regarded as problematic below approximately 60 per cent, frequently reflects drug leaching into the continuous aqueous phase during preparation or an unfavourable polymer-to-drug ratio, and is addressed by increasing polymer concentration relative to drug, reducing preparation temperature to slow drug diffusion out of the forming particle, or substituting a co-polymer offering more favourable drug-retention characteristics.

Poor colloidal stability, evidenced by particle aggregation over storage time, generally indicates an inadequate zeta potential and is remediated through the addition of a steric stabiliser such as polyvinyl alcohol or polyethylene glycol, or through reduction of the ionic strength of the surrounding medium, which otherwise screens electrostatic repulsion between particles and promotes aggregation. Aggregation occurring specifically during storage at refrigerated or ambient temperature, distinct from aggregation observed immediately following preparation, often reflects underlying temperature sensitivity of the colloidal system and is best addressed through lyophilisation in the presence of an appropriate cryoprotectant, commonly trehalose at approximately 5 per cent or mannitol at approximately 4 per cent, converting the unstable liquid dispersion into a stable dry powder for reconstitution immediately prior to use, with storage of the lyophilised product at minus 20 degrees Celsius providing a further margin of stability. Low overall drug loading, distinct from low encapsulation efficiency, generally reflects poor intrinsic affinity between the drug and the chosen carrier polymer and is addressed through systematic screening of alternative polymer types or through hot-melt extrusion processing to generate an amorphous molecular dispersion of drug within the carrier matrix, thereby improving the thermodynamic compatibility between the two components.